EUR 2.85
(-2.9%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 233.4 Million CAD | -15.05% |
2022 | 274.74 Million CAD | 11.59% |
2021 | 246.21 Million CAD | 252.69% |
2020 | 69.81 Million CAD | 71.34% |
2019 | 40.74 Million CAD | 57.17% |
2018 | 25.92 Million CAD | 133.26% |
2017 | 11.11 Million CAD | 6.67% |
2016 | 10.41 Million CAD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 234.46 Million CAD | 3.15% |
2024 Q1 | 227.3 Million CAD | -2.61% |
2024 Q3 | 238.46 Million CAD | 1.71% |
2023 Q3 | 265.16 Million CAD | -1.09% |
2023 Q1 | 273.83 Million CAD | -0.33% |
2023 Q2 | 268.09 Million CAD | -2.1% |
2023 FY | 233.4 Million CAD | -15.05% |
2023 Q4 | 233.4 Million CAD | -11.98% |
2022 FY | 274.74 Million CAD | 11.59% |
2022 Q4 | 274.74 Million CAD | -11.28% |
2022 Q3 | 309.65 Million CAD | 2.52% |
2022 Q2 | 302.03 Million CAD | 3.95% |
2022 Q1 | 290.56 Million CAD | 18.01% |
2021 Q2 | 200.07 Million CAD | 20.11% |
2021 Q4 | 246.21 Million CAD | 5.14% |
2021 Q3 | 234.18 Million CAD | 17.05% |
2021 FY | 246.21 Million CAD | 252.69% |
2021 Q1 | 166.57 Million CAD | 138.61% |
2020 Q1 | 69.33 Million CAD | 70.16% |
2020 Q4 | 69.81 Million CAD | -7.99% |
2020 Q2 | 73.15 Million CAD | 5.52% |
2020 Q3 | 75.87 Million CAD | 3.72% |
2020 FY | 69.81 Million CAD | 71.34% |
2019 FY | 40.74 Million CAD | 57.17% |
2019 Q4 | 40.74 Million CAD | -19.64% |
2019 Q1 | 39.12 Million CAD | 50.93% |
2019 Q3 | 50.7 Million CAD | 6.35% |
2019 Q2 | 47.67 Million CAD | 21.86% |
2018 FY | 25.92 Million CAD | 133.26% |
2018 Q4 | 25.92 Million CAD | 117.51% |
2018 Q1 | - CAD | -100.0% |
2018 Q3 | 11.91 Million CAD | 0.0% |
2017 Q4 | 11.11 Million CAD | 0.0% |
2017 FY | 11.11 Million CAD | 6.67% |
2016 FY | 10.41 Million CAD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | 25.87 Million EUR | -801.909% |
Redcare Pharmacy NV | 1.04 Billion EUR | 77.744% |